The retrieval provided starting points but I'll fill in the full picture comprehensively from established medical knowledge and the retrieved sources.
Hypothyroidism
Overview
Hypothyroidism is a clinical syndrome resulting from insufficient thyroid hormone action in peripheral tissues, due either to inadequate production or (rarely) resistance to hormone action. It affects approximately 5% of the general population, with a female-to-male ratio of ~10:1.
Classification & Etiology
| Type | Location of Defect | Common Causes |
|---|
| Primary | Thyroid gland | Hashimoto's thyroiditis, post-radioiodine, post-thyroidectomy, iodine deficiency, drugs (amiodarone, lithium, checkpoint inhibitors) |
| Secondary | Pituitary | Pituitary adenoma, Sheehan's syndrome, hypophysitis |
| Tertiary | Hypothalamus | Hypothalamic lesions, TRH deficiency |
| Peripheral | Tissue resistance | Thyroid hormone receptor mutations (rare) |
Over 95% of cases are primary hypothyroidism.
Primary Hypothyroidism – Key Causes
1. Autoimmune (Hashimoto's Thyroiditis) — the most common cause in iodine-sufficient regions
- Goitrous form (Hashimoto's thyroiditis) or atrophic form (atrophic thyroiditis)
- Characterized by anti-TPO and anti-thyroglobulin antibodies
- Lymphocytic infiltration → progressive destruction of follicular cells
- The autoimmune process gradually reduces thyroid function: first a compensated phase (subclinical hypothyroidism, normal T4 with elevated TSH), then overt hypothyroidism as T4 falls and TSH rises (typically TSH >10 mIU/L) (Harrison's, p. 10696)
2. Iatrogenic
- Post-radioiodine ablation (for Graves' disease or thyroid cancer)
- Post-thyroidectomy (total or subtotal)
- External beam radiation to the neck
3. Drug-Induced
- Amiodarone (iodine-rich; inhibits T4→T3 conversion)
- Lithium (inhibits thyroid hormone synthesis and release)
- Immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4) — immune-related hypothyroidism
- Interferon-alpha, sunitinib
4. Iodine Deficiency — leading cause worldwide
5. Infiltrative Disease — sarcoidosis, amyloidosis, Riedel's thyroiditis
6. Congenital — thyroid agenesis/dysgenesis, dyshormonogenesis (detected by neonatal screening)
Pathophysiology
- Reduced thyroid hormone (T3/T4) → disinhibition of hypothalamic-pituitary axis → elevated TSH
- T3 (active form) acts on nuclear receptors regulating metabolism, thermogenesis, cardiac contractility, CNS development, and lipid metabolism
- Deficiency leads to reduced basal metabolic rate, accumulation of glycosaminoglycans (myxedema), hyperlipidemia, and bradycardia
Clinical Features
Symptoms and signs reflect the slowing of metabolic processes:
Symptoms
- General: fatigue, weight gain, cold intolerance, lethargy
- Skin/hair: dry skin, hair thinning/loss, brittle nails, facial puffiness
- Cardiovascular: bradycardia, dyspnea on exertion, pericardial effusion
- GI: constipation, anorexia, macroglossia
- Neuropsychiatric: cognitive slowing, depression, poor concentration, paresthesias (carpal tunnel syndrome)
- Musculoskeletal: muscle cramps, myalgia, proximal myopathy
- Reproductive: menorrhagia, anovulation, infertility, decreased libido
Signs
- Bradycardia
- Periorbital/facial puffiness (myxedema)
- Non-pitting edema
- Delayed relaxation of deep tendon reflexes ("hung reflexes")
- Goiter (in Hashimoto's) or absent thyroid tissue (atrophic form)
- Hoarse voice, dry coarse skin, carotenemia (yellow tinge)
Diagnosis
Step 1 — TSH Screening (best initial test)
| TSH | Free T4 | Interpretation |
|---|
| Elevated (4.5–10 mIU/L) | Normal | Subclinical hypothyroidism |
| Elevated (>10 mIU/L) | Low | Overt/clinical hypothyroidism |
| Low or normal | Low | Secondary/tertiary hypothyroidism |
| Normal | Normal | Euthyroid |
- TSH is the most sensitive screening test for primary hypothyroidism
- If TSH is elevated, confirm with free T4
Step 2 — Additional Tests
- Anti-TPO antibodies: positive in ~95% of Hashimoto's thyroiditis; confirms autoimmune etiology
- Anti-thyroglobulin antibodies: less specific, may be positive
- Thyroid ultrasound: heterogeneous echotexture in Hashimoto's; not routinely required for diagnosis
- CBC: normocytic or macrocytic anemia may be present
- Lipid panel: hypercholesterolemia (LDL elevated) is common
- CK: elevated in hypothyroid myopathy
- Prolactin: may be mildly elevated (TRH stimulates prolactin)
Management
Overt Hypothyroidism
Levothyroxine (T4) is the standard treatment (Endocrine-Related Adverse Conditions, p. 12).
| Parameter | Details |
|---|
| Starting dose | 1.6 mcg/kg/day (lean body weight) |
| Elderly / cardiac disease | Start low: 25–50 mcg/day; titrate slowly |
| Goal | TSH within normal range (0.5–2.5 mIU/L) |
| Monitoring | Recheck TSH at 6–8 weeks after dose change |
| Steady state | Achieved in ~6 weeks |
Administration tips:
- Take on an empty stomach, 30–60 min before food
- Avoid co-administration with calcium, iron, PPI, soy (impair absorption)
When to add T3 (liothyronine): Controversial. Some patients with persistent symptoms on T4 monotherapy may benefit from combination T3/T4 therapy, though evidence is mixed.
Subclinical Hypothyroidism
| TSH Level | Recommendation |
|---|
| >10 mIU/L | Treat with levothyroxine |
| 4.5–10 mIU/L | Consider treatment if: symptoms present, positive anti-TPO, pregnancy/planning pregnancy, age <65 |
| Elderly (>65) | Caution; TSH up to 10 may be age-appropriate; treat if clearly symptomatic |
Special Populations
- Pregnancy: TSH target <2.5 mIU/L in first trimester (uncontrolled hypothyroidism risks miscarriage, preeclampsia, fetal neurodevelopmental impairment); increase levothyroxine dose ~25–30% on pregnancy confirmation
- Congenital hypothyroidism: Treat immediately after birth to prevent cretinism (irreversible intellectual disability); neonatal TSH screening is standard
- Myxedema coma (see below): ICU management required
Myxedema Coma (Severe/Decompensated Hypothyroidism)
A life-threatening emergency (mortality 20–50%) triggered by infection, cold exposure, surgery, or sedatives in a profoundly hypothyroid patient.
Features: altered consciousness, hypothermia, bradycardia, hypoventilation, hyponatremia, hypoglycemia
Management:
- IV levothyroxine 200–400 mcg loading dose, then 50–100 mcg/day IV
- IV liothyronine (T3) may be added cautiously (faster onset)
- IV hydrocortisone 50–100 mg q8h (empirically cover for adrenal insufficiency before thyroid hormone replacement)
- Mechanical ventilation if needed
- Passive rewarming
- Treat precipitating cause
Complications of Untreated Hypothyroidism
| Complication | Mechanism |
|---|
| Dyslipidemia | Reduced LDL receptor expression → hypercholesterolemia |
| Cardiovascular disease | Hypertension, accelerated atherosclerosis |
| Pericardial/pleural effusion | Glycosaminoglycan accumulation |
| Infertility / pregnancy loss | Anovulation, inadequate corpus luteum support |
| Myxedema coma | Severe decompensation |
| Neurodevelopmental delay | Congenital or maternal hypothyroidism |
Differential Diagnosis
- Depression (mimics cognitive/affective symptoms)
- Chronic fatigue syndrome / fibromyalgia
- Nephrotic syndrome (low T4 due to protein loss, but TSH normal)
- Euthyroid sick syndrome (low T3/T4 with normal/low TSH in critical illness)
- Anemia
- Congestive heart failure (edema, fatigue overlap)
Key Takeaways
- TSH is the best screening test; low free T4 confirms overt disease
- Hashimoto's thyroiditis is the most common cause in developed nations
- Levothyroxine is the treatment of choice; dose-adjusted by TSH at 6–8 week intervals
- Pregnancy and myxedema coma are critical scenarios requiring urgent management
- Subclinical hypothyroidism with TSH >10 should generally be treated; the 4.5–10 range requires individualized decision-making